| 0.0007 0 (0%) | 09-08 10:20 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.02 | 1-year : | 0.03 |
| Resists | First : | 0.02 | Second : | 0.03 |
| Pivot price | 0 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0 |
| MA(100) : | 0 |
MA(250) : | 0.05 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.4 | D(3) : | 2.4 |
| RSI | RSI(14): 34.7 | |||
| 52-week | High : | 0.41 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CARM ] has closed above bottom band by 21.1%. Bollinger Bands are 83.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Fri, 05 Dec 2025
Carisma Announces Delisting from Nasdaq and SEC Deregistration - PR Newswire
Tue, 14 Oct 2025
CARM Stock Price and Chart — OTC:CARM - TradingView
Fri, 10 Oct 2025
Carisma Therapeutics stock plunges after Nasdaq delisting notice - Investing.com
Tue, 24 Jun 2025
Carisma Therapeutics, OrthoCellix enter definitive merger agreement - Yahoo Finance
Thu, 24 Apr 2025
Carisma Therapeutics (CARM) Stock Price, News & Analysis - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 3.014e+007 (%) |
| Held by Institutions | 23 (%) |
| Shares Short | 787 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.418e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 15.2 % |
| Operating Margin | 96.8 % |
| Return on Assets (ttm) | 33 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 296 |
| Sales Per Share | 6.57875e+007 |
| EBITDA (p.s.) | 3.16e+007 |
| Qtrly Earnings Growth | 0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.02 |
| Dividend | 0 |
| Forward Dividend | 1.29e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|